DEF 14A: Chain Bridge I Seeks Extension to Complete Business Combination with Phytanix Bio

Chain Bridge I is seeking shareholder approval to extend the deadline for completing a business combination from November 15, 2024, to November 15, 2025, to allow more time to finalize its merger with Phytanix Bio.

Summary

• Chain Bridge I (CBRG) is holding an Extraordinary General Meeting on November 8, 2024, to vote on a proposal to extend the deadline for completing a business combination from November 15, 2024, to November 15, 2025.
• The primary reason for the extension is to provide more time to complete the proposed business combination with Phytanix Bio, announced on July 22, 2024.
• The business combination involves CBRG merging with Phytanix Bio, with HoldCo (CB Holdings, Inc.) becoming a publicly listed holding company named Phytanix, Inc., expected to be listed on the Nasdaq Capital Market under the ticker symbol PHYX.
• The aggregate consideration for the Phytanix Business Combination is derived from an equity value of $58 million.
• HoldCo will issue 17,000 shares of HoldCo Preferred Stock and issue additional shares of HoldCo Preferred Stock in exchange for certain short term debt obligations of Phytanix.
• Shareholders of CBRG have the option to redeem their shares for a pro rata portion of the Trust Account, estimated to be approximately $11.33 per share as of the record date, if the extension is approved.
• If the extension is approved, the CBRG Sponsor will contribute $0.01 per public share per month to the trust account, commencing on November 16, 2024, until the earlier of the extended termination date, the consummation of an initial business combination, or the winding up of the company.
• If the extension is not approved, CBRG will liquidate, and shareholders will receive their pro rata share of the Trust Account, after settling creditor claims.
• The Phytanix Business Combination is expected to close in the first quarter of 2025, pending shareholder approval and fulfillment of customary closing conditions.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting both the potential benefits and risks of the proposed extension. The sentiment is slightly positive due to the potential for completing the Phytanix Business Combination, but tempered by the risks associated with redemptions and potential liquidation.

Positives

• The extension allows CBRG shareholders the opportunity to vote on the Phytanix Business Combination.
• Shareholders retain the right to redeem their shares if they disapprove of the Phytanix Business Combination.
• The CBRG Sponsor's contribution of $0.01 per share per month provides additional funds to the Trust Account.

Negatives

• If the extension is not approved, CBRG will liquidate, and the Private Warrants will expire worthless.
• Redemptions in connection with the extension vote could significantly reduce the amount remaining in the Trust Account.
• If the Amendment Proposal passes and we have not completed a an Initial Business Combination by November 9, 2024, we will be in violation of Nasdaq listing standards.

Risks

• The Phytanix Business Combination may not be consummated even if the extension is approved.
• Redemptions could impact CBRG's ability to list the combined company's securities on a national exchange or leave insufficient cash to consummate the Phytanix Business Combination.
• Nasdaq may delist CBRG's shares if the business combination is not completed by November 9, 2024.
• CBRG could be deemed an investment company, requiring burdensome compliance and potentially leading to liquidation.
• If the securities held in the Trust Account are liquidated and held in cash, the cash balances of the Trust Accounts bank accounts may exceed the FDIC insurance limitations.

Future Outlook

The Company intends to complete the Phytanix Business Combination in the first quarter of 2025, pending shareholder approval and the fulfillment of other customary closing conditions. If the Business Combination is not completed, the Company will seek other business combination opportunities.

Management Comments

• The Board of Directors believes the Company's shareholders will benefit from the Company consummating an Initial Business Combination and is proposing the Amendment Proposal to extend the date by which the Company has to complete the Initial Business Combination to allow you as a shareholder the benefit of voting for the Initial Business Combination and remaining a shareholder in the post Initial-Business Combination company, if you desire.

Industry Context

The announcement reflects the ongoing trend of SPACs seeking extensions to complete business combinations, often due to market conditions or challenges in finding suitable targets. The success of the extension vote and the subsequent merger will be indicative of investor sentiment towards SPACs and the specific target company, Phytanix Bio.

Comparison to Industry Standards

• The $58 million equity value for Phytanix is relatively small compared to some other SPAC mergers, which can range from hundreds of millions to billions of dollars.
• The monthly contribution of $0.01 per share by the sponsor is a common incentive to encourage shareholders to approve the extension and maintain their investment.
• Comparable companies in the SPAC market include those that have recently sought extensions, such as Gores Metropoulos II, Inc. which extended its deadline to merge with Sonder Holdings Inc.
• The redemption rate in connection with the extension vote will be a key indicator of shareholder confidence, similar to how redemption rates are monitored in other SPAC transactions like the recent combination of D and Z Media Acquisition Corp. with Bleecker Street.

Stakeholder Impact

• Shareholders: Impacted by the potential extension, redemption rights, and the outcome of the Phytanix Business Combination.
• Employees: The future of the company and potential job security depend on the completion of the business combination.
• Creditors: Their claims will be prioritized in the event of liquidation.
• Sponsor: Faces potential loss of investment if the business combination is not completed.

Next Steps

• Shareholders will vote on the extension proposal on November 8, 2024.
• If the extension is approved, the Company will continue to work towards completing the Phytanix Business Combination.
• The Company intends to file as soon as possible a registration statement on Form S-4 (the Registration Statement), to give the Public Holders the opportunity to consider and vote on the Phytanix Business Combination.

Key Dates

Keywords

Business Combination, Phytanix Bio, Extension, Redemption, Trust Account, SPAC, Merger, CBRG, Shareholders, Liquidation